Printer Friendly

Research and Markets: The US Parkinson's Disease Market Will Experience A Considerable Drop In Market Share, From 32% In 2009 To 25% In 2019.

DUBLIN -- Research and Markets(http://www.researchandmarkets.com/research/210b1d/pipeline_and_comme) has announced the addition of the "Pipeline and Commercial Insight: Parkinson's Disease - Reformulations sustain market growth in the absence of therapeutic breakthroughs" report to their offering.

In 2009, the Parkinson's disease market generated $2.2bn across the seven major markets. As the market approaches maturity, Datamonitor forecasts the growth to slow from a compound annual growth rate of 7.9% (2005-09) to 2.2% (2009-19), as pipeline entries partially offset the generic erosion of key brand sales. Quantify the historic (2005-09) and future (2010-19) size of the Parkinson's disease market. Comprehensive epidemiology review of the Parkinson's disease market authored by trained epidemiologists. Review of the current Parkinson's disease drug dynamics, including detailed profiles. Commercial and clinical assessment of key late-stage pipeline drugs, with key opinion leader comment and region-specific sales forecasts to 2019. Analysis of current treatment approaches, patient acquisition and clinical unmet needs. The major Parkinson's disease growth driver over the 2005-09 period was the dopamine agonist class, which accounted for nearly half the Parkinson's disease market sales, supported by the continued uptake of the newer catechol-O-methyltransferase (COMT) inhibitor and monoamine oxidase inhibitor (MAOI) classes. Parkinson's disease market growth is set to slump, as an unimpressive late-stage pipeline will fail to offset generic incursion. The US market will experience a considerable drop in market share, from 32% in 2009 to 25% in 2019, as generics take hold. New reformulations and the novel adenosine A2a receptor antagonist drugs do not offer the benefits or differentiation required to usurp traditional therapies.

Key Questions Include:

What are the commercial prospects of current and potential therapies for Parkinson's disease over the next 10 years? How will the impact of recent patent expiries and new product launches affect the Parkinson's disease market? How receptive is the market to new pipeline drugs and reformulations, in light of the availability of generic dopamine agonists? How will the new class of adenosine A2a receptor antagonists perform in the future marketplace? What are the current treatment approaches and unmet medical needs in Parkinson's disease?

Key Topics Covered:

* EXECUTIVE SUMMARY

* OVERVIEW

* PATIENT POTENTIAL

* EPIDEMIOLOGY

* MARKET OVERVIEW

* BRAND DYNAMICS

* PIPELINE OVERVIEW AND R&D DYNAMICS

* PIPELINE DRUG ANALYSIS AND FORECASTS: DOPAMINERGICS

* PIPELINE DRUG ANALYSIS AND FORECASTS: DOPAMINE AGONISTS

* PIPELINE DRUG ANALYSIS AND FORECASTS: MONOAMINE OXIDASE INHIBITORS

* PIPELINE DRUG ANALYSIS AND FORECASTS: ADENOSINE A2A RECEPTOR ANTAGONISTS

* PIPELINE DRUG ANALYSIS AND FORECASTS: NEUROPROTECTIVE DRUGS

* OTHER DRUG CLASSES

* INNOVATIVE EARLY-STAGE APPROACHES

* BIBLIOGRAPHY

* APPENDIX

For more information visit http://www.researchandmarkets.com/research/210b1d/pipeline_and_comme.

Source: Datamonitor
COPYRIGHT 2011 Business Wire
No portion of this article can be reproduced without the express written permission from the copyright holder.
Copyright 2011 Gale, Cengage Learning. All rights reserved.

Article Details
Printer friendly Cite/link Email Feedback
Publication:Business Wire
Date:Jan 20, 2011
Words:527
Previous Article:Perella Weinberg Partners Names William H. Parkerson as Managing Director.
Next Article:Insect Eyes Inspire Improved Solar Cells.
Topics:

Terms of use | Copyright © 2017 Farlex, Inc. | Feedback | For webmasters